A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Narayan AdhikariAhit Agni BiswasAjay GogiaRanjit Kumar SahooAjay GargAshima NehraMehar Chand SharmaSuman BhaskerManmohan SinghVishnubhatla SreenivasRohan ChawlaGarima JoshiLalit KumarSubhash ChanderPublished in: Journal of neuro-oncology (2018)
In patients with PCNSL, reduced dose WBRT after CR to HDMTX based chemotherapy may lead to suboptimal clinical outcome due to higher risk of recurrence, progression and early death. Trial Registration No CTRI/2015/10/006268.
Keyphrases
- high dose
- locally advanced
- newly diagnosed
- low dose
- early stage
- liver failure
- stem cell transplantation
- rectal cancer
- oxidative stress
- radiation therapy
- clinical trial
- squamous cell carcinoma
- study protocol
- white matter
- resting state
- diffuse large b cell lymphoma
- phase iii
- drug induced
- multiple sclerosis
- respiratory failure
- cerebrospinal fluid
- free survival
- functional connectivity
- hepatitis b virus
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- mechanical ventilation